GEG
Great Elm Group, Inc.
There isn't enough reported data to score GEG yet.
NVO
Novo Nordisk A/S
NVO's fundamentals are mixed: it turned 15% of its revenue into free cash flow, but its operating margin fell 3 points to 43%. Its PE isn't a useful guide right now because of how its recent earnings were reported.
GEG Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Weak | |
| Healthy | |
| Strong |
GEG's cash flow and balance sheet are currently healthy, and its revenue is stable, but its profitability is weak.
NVO Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Stable | |
| Healthy |
NVO's revenue, profitability and balance sheet are currently healthy, and its cash flow is stable.
GEG PE Valuation
GEG has no meaningful PE right now: it lost money over the past year.
NVO PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 10x | $40.65 | — |
| Cheap | 14x | $53.56 | +32% |
| Fair | 27x | $103 | +154% |
| Expensive | 39x | $152 | +273% |
Historical ranges are pointers, not guarantees.
NVO's PE is 10x, but its earnings don't support one, so it isn't a reliable read right now.
GEG Forward outlook
There aren't enough analyst estimates for GEG to show an outlook.
NVO Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Stable | |
| Growth | |
| Weakening | |
| Limited | |
| Low |
Analysts expect NVO's revenue to grow, but its profitability to weaken. However, they disagree widely on these estimates.
GEG Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$1.07 | -1883% |
| Q2 2026 | -$1.17 | -408% |
| Q1 2026 | -$0.76 | -$0.69 |
| Q4 2025 | -$0.48 | -$0.48 |
| Q3 2025 | $0.06 | +$0.11 |
| Q2 2025 | $0.38 | +$0.43 |
| Q1 2025 | -$0.07 | +$0.08 |
| Q4 2024 | $0.00 | -100% |
GEG has swung to a loss: it lost $1.07 per share over the past year, after a profit the year before.
NVO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | $3.89 | +4.9% |
| Q1 2026 | $4.07 | +17% |
| Q4 2025 | $3.42 | +1.8% |
| Q3 2025 | $3.47 | +10% |
| Q2 2025 | $3.71 | +24% |
| Q1 2025 | $3.49 | +18% |
| Q4 2024 | $3.36 | +21% |
| Q3 2024 | $3.15 | +27% |
NVO has the edge over GEG on earnings quality, reporting a profit while its opponent remains loss making.
GEG Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $3.3M | -69% |
| Q2 2026 | $10.6M | +88% |
| Q1 2026 | $3.4M | +6.5% |
| Q4 2025 | $3M | -14% |
| Q3 2025 | $10.8M | +170% |
| Q2 2025 | $5.6M | -37% |
| Q1 2025 | $3.2M | +15% |
| Q4 2024 | $3.5M | +24% |
GEG's revenue has slid since its 2022 peak: $3M last quarter, down 69% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -104% | -70 points |
| Q2 2026 | -20% | +6.6 points |
| Q1 2026 | -116% | -37 points |
| Q4 2025 | -141% | -84 points |
| Q3 2025 | -35% | +16 points |
| Q2 2025 | -26% | -5.9 points |
| Q1 2025 | -80% | -13 points |
| Q4 2024 | -56% | +39 points |
GEG's operating margin was −104% last quarter, down 70 points from the same quarter a year ago.
NVO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $11.7B | +2.1% |
| Q1 2026 | $14.4B | +24% |
| Q4 2025 | $11.8B | -7.6% |
| Q3 2025 | $11.1B | +5.1% |
| Q2 2025 | $11.4B | +13% |
| Q1 2025 | $11.6B | +19% |
| Q4 2024 | $12.7B | +30% |
| Q3 2024 | $10.6B | +21% |
NVO has the edge over GEG on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 34% | -9 points |
| Q1 2026 | 62% | +12 points |
| Q4 2025 | 40% | -2.8 points |
| Q3 2025 | 32% | -16 points |
| Q2 2025 | 44% | +5.4 points |
| Q1 2025 | 50% | +1 points |
| Q4 2024 | 43% | +2.2 points |
| Q3 2024 | 47% | +1.6 points |
NVO has the edge over GEG on profitability, with a higher operating margin.
GEG Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$10.6M | -378% |
| Q2 2026 | $7.9M | +265% |
| Q1 2026 | $5.8M | +$7.2M |
| Q4 2025 | -$1.9M | +$2.2M |
| Q3 2025 | $3.8M | +$9.6M |
| Q2 2025 | $2.2M | -27% |
| Q1 2025 | -$1.3M | -198% |
| Q4 2024 | -$4M | +$9.7M |
GEG usually generates cash, though not every quarter: the latest was −$11M, but it generated $1M over the past year.
NVO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $6.3B | +73% |
| Q1 2026 | $1.8B | +20% |
| Q4 2025 | -$5.4B | -$4.7B |
| Q3 2025 | $4.6B | -2.1% |
| Q2 2025 | $3.6B | -34% |
| Q1 2025 | $1.5B | +89% |
| Q4 2024 | -$632.6M | +$390.5M |
| Q3 2024 | $4.7B | +3.3% |
NVO still generates free cash flow, though less than at its 2026 peak: $7.3B over the past year.
GEG Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -1.8% | -554K shares |
| 1 year | +2.6% | +763K shares |
| 3 years | +2.5% | +738K shares |
| 5 years | +15% | +4M shares |
| Available history | +17% | +4.3M shares |
GEG has 30M diluted shares, up 2.6% from a year ago, despite $7M in buybacks over the past year.
| Quarter | Spent |
|---|---|
| Q3 2026 | $581,000 |
| Q2 2026 | $596,000 |
| Q1 2026 | $2.8M |
| Q4 2025 | $2.6M |
| Q3 2025 | $756,000 |
| Q2 2025 | $922,000 |
| Q1 2025 | $1.1M |
| Q4 2024 | $3.1M |
GEG spent $7M buying back its own shares over the past year, up 13% from the year before.
NVO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.3% | -12.9M shares |
| 1 year | -0.2% | -11M shares |
| 3 years | -1.5% | -66.8M shares |
| 5 years | -3.8% | -177M shares |
| Available history | -6.5% | -311M shares |
NVO has the edge over GEG on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q2 2026 | $520M |
| Q1 2026 | $356.7M |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | $206.3M |
| Q4 2024 | $1.1B |
| Q3 2024 | $357.4M |
NVO spent $877M buying back its own shares over the past year, down 48% from the year before.
GEG Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2022 | -15.6x | Net Cash |
| Q1 2022 | -12.4x | Net Cash |
| Q4 2021 | -6.4x | Net Cash |
| Q3 2021 | -4.3x | Net Cash |
| Q4 2019 | 8.6x | High |
GEG has more cash than debt.
NVO Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | 0.5x | Very low |
| Q1 2026 | 0.7x | Very low |
| Q4 2025 | 0.6x | Very low |
| Q3 2025 | 0.4x | Very low |
| Q2 2025 | 0.5x | Very low |
| Q1 2025 | 0.5x | Very low |
| Q4 2024 | 0.6x | Very low |
| Q3 2024 | -0.0x | Very low |
NVO's net debt is less than a year of its operating earnings (EBITDA).
GEG Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 48.2 | Neutral |
| Stochastic | 22.8 | Neutral |
GEG's weekly RSI is 48 (neutral) and its Stochastic is 23 (neutral).
NVO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 43.0 | Neutral |
| Stochastic | 27.0 | Neutral |
NVO's weekly RSI is 43 (neutral) and its Stochastic is 27 (neutral).
GEG PE vs Healthcare Sector
| Metric | GEG | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
GEG has no meaningful PE right now: it lost money over the past year.
NVO PE vs Healthcare Sector
| Metric | NVO | Sector median | Relative |
|---|---|---|---|
| PE | 10x | 26x | 60% below |
| PE % | 6 | 29 | 23 pts below |
NVO is trading at 10x earnings, a 60% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
GEG Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $2.16 | 0% above |
| 20 week MA | $2.17 | 0.5% below |
| 50 week MA | $2.20 | 1.8% below |
| 100 week MA | $2.17 | 0.5% below |
| 200 week MA | $2.06 | 4.9% above |
GEG has the edge over NVO on trend strength, trading above more of its moving averages.
NVO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $39.2 | 3.7% above |
| 20 week MA | $43.9 | 7.4% below |
| 50 week MA | $45.3 | 10% below |
| 100 week MA | $56.3 | 28% below |
| 200 week MA | $80.7 | 50% below |
NVO has bounced recently, but its long-term trend is still down: it's above its 8-week average, but 50% below its 200-week average.
GEG Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $3.48 | $2.72 | -22% |
| 2021 | $2.72 | $2.07 | -24% |
| 2022 | $2.07 | $1.99 | -3.9% |
| 2023 | $1.99 | $1.94 | -2.5% |
| 2024 | $1.94 | $1.82 | -6.2% |
| 2025 | $1.82 | $2.44 | +34% |
| 2026 YTD | $2.44 | $2.16 | -11% |
GEG has the edge over NVO on returns for 2026, with the stronger performance.
NVO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $29.1 | $34.7 | +19% |
| 2021 | $34.7 | $54.2 | +56% |
| 2022 | $54.2 | $67.0 | +24% |
| 2023 | $67.0 | $103.5 | +54% |
| 2024 | $103.5 | $87.4 | -16% |
| 2025 | $87.4 | $52.4 | -40% |
| 2026 YTD | $52.4 | $40.7 | -22% |
NVO has finished higher in four of the last six years, two of them by more than 50%. It's down 22% so far in 2026.